» Articles » PMID: 16682487

Interleukin-6 Release from Human Abdominal Adipose Cells is Regulated by Thyroid-stimulating Hormone: Effect of Adipocyte Differentiation and Anatomic Depot

Overview
Date 2006 May 10
PMID 16682487
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Adipose cells are extrathyroidal targets of thyroid-stimulating hormone (TSH). TSH stimulates interleukin-6 (IL-6) release from adipocytes. We examined TSH responsiveness as a function of stage of differentiation or adipose tissue depot in cultured adipose cells and determined the effect of TSH on extrathyroidal IL-6 production in vivo. Stromal preadipocytes, isolated from human abdominal subcutaneous or omental adipose tissue, and their differentiated counterparts were studied. IL-6 protein concentration in the medium was measured after TSH stimulation. Basal IL-6 release was greater for preadipocytes than differentiated adipocytes, whether derived from subcutaneous or omental fat depots. A depot-dependent effect (omental > subcutaneous) on basal IL-6 release was observed for preadipocytes (1.6-fold, P < 0.05); a similar trend for differentiated adipocytes was not significant (6.2-fold, P > 0.05). IL-6 responsiveness to TSH was observed upon differentiation, but only for subcutaneous adipocytes (1.9-fold over basal, P < 0.001). To determine if TSH could stimulate IL-6 release from extrathyroidal tissues in vivo, we measured serum IL-6 levels from five thyroidectomized patients who received recombinant human (rh) TSH and found that levels increased by threefold on days 3 and 4 (P < 0.05) after its administration. Our data demonstrate that stage of differentiation and fat depot origin affect basal and TSH-stimulated IL-6 release from adipose cells in culture. Furthermore, rhTSH elevates serum IL-6 response in thyroidectomized patients, indicating an extrathyroidal site of TSH action.

Citing Articles

Mediating role of triglyceride-glucose index and its derivatives in the relationship between central obesity and Hashimoto thyroiditis in type 2 diabetes.

Zhai Y, Lin C, Li J, Qiu H, Wu F, Wang Y Lipids Health Dis. 2024; 23(1):411.

PMID: 39702130 PMC: 11657283. DOI: 10.1186/s12944-024-02402-8.


Endothelial Dysfunction in Obesity and Therapeutic Targets.

Engin A Adv Exp Med Biol. 2024; 1460:489-538.

PMID: 39287863 DOI: 10.1007/978-3-031-63657-8_17.


Free triiodothyronine (FT3)-to-free thyroxine (FT4) ratio identified as a risk factor for gestational diabetes in euthyroid pregnant women: insights from a Chinese population cohort study.

Zhao X, Sun J, Yuan N, Zhang X Front Endocrinol (Lausanne). 2023; 14:1281285.

PMID: 38053730 PMC: 10694352. DOI: 10.3389/fendo.2023.1281285.


Mediation effects of thyroid function in the associations between phthalate exposure and lipid metabolism in adults.

Huang H, Cheng P, Siao C, Lo Y, Chou W, Huang P Environ Health. 2022; 21(1):61.

PMID: 35778735 PMC: 9248169. DOI: 10.1186/s12940-022-00873-9.


Combined prognostic value of preoperative serum thyrotrophin and thyroid hormone concentration in papillary thyroid cancer.

Liu Y, Huang Y, Mo G, Zhou T, Hou Q, Shi C J Clin Lab Anal. 2022; 36(7):e24503.

PMID: 35666615 PMC: 9279971. DOI: 10.1002/jcla.24503.